235 related articles for article (PubMed ID: 16988654)
1. Histone deacetylase inhibitors as therapeutics for polyglutamine disorders.
Butler R; Bates GP
Nat Rev Neurosci; 2006 Oct; 7(10):784-96. PubMed ID: 16988654
[TBL] [Abstract][Full Text] [Related]
2. [Histone deacetylase inhibitors as therapeutic agents for polyglutamine disorders].
Jiang H; Jia D; Tang B
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2010 Feb; 27(1):52-5. PubMed ID: 20140868
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of disease: Histone modifications in Huntington's disease.
Sadri-Vakili G; Cha JH
Nat Clin Pract Neurol; 2006 Jun; 2(6):330-8. PubMed ID: 16932577
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic application of histone deacetylase inhibitors for central nervous system disorders.
Kazantsev AG; Thompson LM
Nat Rev Drug Discov; 2008 Oct; 7(10):854-68. PubMed ID: 18827828
[TBL] [Abstract][Full Text] [Related]
5. [Molecular biology of polyglutamine diseases].
Owecki M; Kozubski W
Postepy Hig Med Dosw; 2002; 56(6):779-88. PubMed ID: 12661407
[TBL] [Abstract][Full Text] [Related]
6. Transcriptional alterations and chromatin remodeling in polyglutamine diseases.
Helmlinger D; Tora L; Devys D
Trends Genet; 2006 Oct; 22(10):562-70. PubMed ID: 16911843
[TBL] [Abstract][Full Text] [Related]
7. The pathogenic mechanisms of polyglutamine diseases and current therapeutic strategies.
Bauer PO; Nukina N
J Neurochem; 2009 Sep; 110(6):1737-65. PubMed ID: 19650870
[TBL] [Abstract][Full Text] [Related]
8. Histone deacetylase inhibitors as novel anti-inflammatory agents.
Adcock IM
Curr Opin Investig Drugs; 2006 Nov; 7(11):966-73. PubMed ID: 17117583
[TBL] [Abstract][Full Text] [Related]
9. Pathogenesis of polyglutamine disorders: aggregation revisited.
Michalik A; Van Broeckhoven C
Hum Mol Genet; 2003 Oct; 12 Spec No 2():R173-86. PubMed ID: 14504263
[TBL] [Abstract][Full Text] [Related]
10. [The advances in research on phosphorylation of polyglutamine disease].
Zhou YF; Jiang H; Tang JG; Tang BS
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Aug; 25(4):414-7. PubMed ID: 18683139
[TBL] [Abstract][Full Text] [Related]
11. Huntington's disease: which drugs might help patients?
Hannan AJ
IDrugs; 2004 Apr; 7(4):351-8. PubMed ID: 15057641
[TBL] [Abstract][Full Text] [Related]
12. Optineurin immunoreactivity in neuronal nuclear inclusions of polyglutamine diseases (Huntington's, DRPLA, SCA2, SCA3) and intranuclear inclusion body disease.
Mori F; Tanji K; Toyoshima Y; Yoshida M; Kakita A; Takahashi H; Wakabayashi K
Acta Neuropathol; 2012 May; 123(5):747-9. PubMed ID: 22318854
[No Abstract] [Full Text] [Related]
13. Histone deacetylase inhibitors and demethylating agents: clinical development of histone deacetylase inhibitors for cancer therapy.
Piekarz RL; Sackett DL; Bates SE
Cancer J; 2007; 13(1):30-9. PubMed ID: 17464244
[TBL] [Abstract][Full Text] [Related]
14. Cytoprotective effect of novel histone deacetylase inhibitors against polyglutamine toxicity.
Kariya S; Hirano M; Uesato S; Nagai Y; Nagaoka Y; Furiya Y; Asai H; Fujikake N; Toda T; Ueno S
Neurosci Lett; 2006 Jan; 392(3):213-5. PubMed ID: 16199124
[TBL] [Abstract][Full Text] [Related]
15. Polyglutamine disease: acetyltransferases awry.
Hughes RE
Curr Biol; 2002 Feb; 12(4):R141-3. PubMed ID: 11864588
[TBL] [Abstract][Full Text] [Related]
16. CAG repeat disorder models and human neuropathology: similarities and differences.
Yamada M; Sato T; Tsuji S; Takahashi H
Acta Neuropathol; 2008 Jan; 115(1):71-86. PubMed ID: 17786457
[TBL] [Abstract][Full Text] [Related]
17. Histone deacetylase inhibitors: a novel therapeutic approach to Huntington's disease (complex mechanism of neuronal death).
Sadri-Vakili G; Cha JH
Curr Alzheimer Res; 2006 Sep; 3(4):403-8. PubMed ID: 17017871
[TBL] [Abstract][Full Text] [Related]
18. Histone deacetylases--an important class of cellular regulators with a variety of functions.
Hildmann C; Riester D; Schwienhorst A
Appl Microbiol Biotechnol; 2007 Jun; 75(3):487-97. PubMed ID: 17377789
[TBL] [Abstract][Full Text] [Related]
19. Discovery, biological activity, synthesis and potential therapeutic utility of naturally occurring histone deacetylase inhibitors.
Newkirk TL; Bowers AA; Williams RM
Nat Prod Rep; 2009 Oct; 26(10):1293-320. PubMed ID: 19779641
[No Abstract] [Full Text] [Related]
20. Chromatin acetylation status in the manifestation of neurodegenerative diseases: HDAC inhibitors as therapeutic tools.
Anne-Laurence B; Caroline R; Irina P; Jean-Philippe L
Subcell Biochem; 2007; 41():263-93. PubMed ID: 17484132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
